Ixazomib citrate
| CAS No. | 1239908-20-3 | Cat. No. | BCP16600 |
| Name | Ixazomib citrate | ||
| Synonyms | MLN9708; MLN-9708; MLN 9708;Ixazomib-prodrug; | ||
| Formula | C20H23BCl2N2O9 | M. Wt | 517.119 |
| Description | MLN9708, also known as ixazomib citrate, is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN9708, compared with bortezomib, has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinical studies. | ||
| Pathways | Protease/Metabolic Enzyme Others Pathway | ||
| Targets | Proteasome Autophagy | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.